Drug General Information
Drug ID
D01PZD
Former ID
DCL000629
Drug Name
Romiplostim
Drug Type
Small molecular drug
Indication Thrombocytopenia [ICD-11: 3B64] Approved [1], [2]
Multiple myeloma [ICD-11: 2A83; ICD-10: C90] Phase 2 [3], [4], [5]
Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 [1], [6]
Discovery agent [ICD-11: N.A.] Investigative [7]
Company
Amgen
Structure
Download
2D MOL

3D MOL

Formula
C15H14N2O
Canonical SMILES
CC1=CC(=C(N1)C=C2C3=CC=CC=C3NC2=O)C
InChI
1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-
InChIKey
WUWDLXZGHZSWQZ-WQLSENKSSA-N
CAS Number
CAS 267639-76-9
PubChem Compound ID
PubChem Substance ID
SuperDrug ATC ID
B02BX04
Target and Pathway
Target(s) Aryl hydrocarbon receptor (AHR) Target Info Modulator [4], [8]
Fibroblast growth factor receptor 1 (FGFR1) Target Info Inhibitor [7]
Platelet-derived growth factor receptor alpha (PDGFRA) Target Info Inhibitor [9]
Platelet-derived growth factor receptor beta (PDGFRB) Target Info Inhibitor [9]
Proto-oncogene c-Ret (RET) Target Info Inhibitor [10]
Thrombopoietin receptor (MPL) Target Info Modulator [2]
Tyrosine-protein kinase Kit (KIT) Target Info Inhibitor [11]
Vascular endothelial growth factor receptor 2 (KDR) Target Info Inhibitor [7]
VEGFR1 messenger RNA (VEGFR1 mRNA) Target Info Inhibitor [11]
KEGG Pathway MAPK signaling pathway
Ras signaling pathway
Rap1 signaling pathway
Calcium signaling pathway
Cytokine-cytokine receptor interaction
PI3K-Akt signaling pathway
Focal adhesion
Gap junction
Regulation of actin cytoskeleton
HTLV-I infection
Pathways in cancer
MicroRNAs in cancer
Glioma
Prostate cancer
Melanoma
Central carbon metabolism in cancer
Choline metabolism in cancer
Choline metabolism in cancer
NetPath Pathway TCR Signaling Pathway
IL4 Signaling Pathway
KitReceptor Signaling Pathway
Panther Pathway Angiogenesis
PDGF signaling pathway
Pathway Interaction Database Signaling events mediated by PTP1B
Beta3 integrin cell surface interactions
S1P3 pathway
Nectin adhesion pathway
Signaling events mediated by TCPTP
SHP2 signaling
S1P1 pathway
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
PDGFR-beta signaling pathway
Validated targets of C-MYC transcriptional repression
PDGF receptor signaling network
Reactome PIP3 activates AKT signaling
Constitutive Signaling by Aberrant PI3K in Cancer
RAF/MAP kinase cascade
RAF/MAP kinase cascade
VEGFA-VEGFR2 Pathway
VEGFR2 mediated cell proliferation
WikiPathways Regulation of Actin Cytoskeleton
MAPK Signaling Pathway
Osteoblast Signaling
Focal Adhesion
PIP3 activates AKT signaling
PDGF Pathway
Signaling Pathways in Glioblastoma
Signaling by PDGF
Signaling by FGFR
Signaling by PDGF
Angiogenesis
References
REF 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6974).
REF 2 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
REF 3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5056).
REF 4 A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer. 2005 Oct 17;93(8):876-83.
REF 5 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
REF 6 Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
REF 7 Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
REF 8 SU5416, a VEGF Receptor Inhibitor and Ligand of the AHR, Represents a New Alternative for Immunomodulation
REF 9 Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
REF 10 Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96.
REF 11 New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.